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LETTERS TO THE EDITOR
Prevalence of
hyperhomocysteinemia in
male hemodialysis patients
To the Editor: The risk for vascular disease is much
higher in hemodialysis patients than in the general popula-
tion [1]. Sex, hypertension, diabetes mellitus, being over-
weight, hyperlipidemia, hyperhomocysteinemia, and smok-
ing are well-established risk factors of cardiovascular
disease [2–3]. This study was undertaken to define the
influence of sex on the prevalence of conventional risk
factors in 54 long-term hemodialysis patients: 24 female,
30 male (mean age in years, 60  12 female and 65 
15 male; mean dialytic age in months, 59  48 female
and 61  55 male). All patients received thrice-weekly
dialysis and ratio of urea clearance times dialysis dura-
tion to the volume that the urea is distributed in (Kt/v)
was always 1.2. No patients at the time of the study
were receiving folate or vitamin B supplements. To-
tal homocysteine (Hcy) was tested by a standard high-
performance liquid chromatography (HPLC) assay and
the following biochemical parameters were also tested:
albumin (g/L), cholesterol (mg/dL), and triglycerides
(mg/dL). Male hemodialysis patients showed signifi-
cantly higher Hcy levels when compared to female hemo-
dialysis patients (66.8  49.1 vs. 40.6  21.7, P  0.02).
Mean plasma—cholesterol (200  40 males vs. 201 
46 females); triglycerides (204  126 males vs. 163  64
females); and albumin (20.0  40.3 males vs. 20.1 
46.2 females) did not show any statistical difference. The
prevalence of hypertension defined as blood pressure
140/80 mm Hg and smoking was similar between the
two groups (76% males vs. 69% females). To our knowl-
edge, this is the first observation of a significant differ-
ence between male and female serum Hcy levels. This
finding may account for the different cardiovascular risk
between the 2 populations of HD patients. Therapeutic
approaches aimed to treat hyperhomocysteinemia should
take into account different cut-off points according to
gender.
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Vitamin C in renal failure—
Pro- or antioxidant?
To the Editor: We observed that vitamin C improved
endothelial function in the resistance vasculature of pa-
tients with chronic renal failure, and that this effect was
abolished by an inhibitor of nitric oxide (NO) synthesis
(l-NMMA). In the current investigation, no intravenous
iron was given in the 4 weeks preceding the study. We
allude to the possible pro-oxidant effect of vitamin C
in the discussion, and it is possible that there may be
heterogenous effects of vitamin C on oxidative stress in
these patients. However, a pro-oxidant effect of vitamin
C in the presence of iron is not consistently observed in
biologic systems. Berger et al [1] demonstrated that in
iron-overloaded plasma, high concentrations of vitamin
C prevented lipid oxidation and was not responsible for
protein or lipid peroxidation in vivo. Proteggenette et al
[2] found no evidence for a pro-oxidant effect on DNA
base pair damage after vitamin C supplementation, in the
presence or absence of iron.
We did not measure blood pH during infusion of vita-
min C so we cannot be certain if it caused local or systemic
acidosis. However, if a substantial change in pH were to
contribute to the enhanced vasodilatation to acetylcholine,
we would expect that it would have been present when
vitamin C was infused alone, would have occurred when
vitamin C was co-infused with the NO donors, and would
have been resistant to the effects of l-NMMA. We did
not observe these nonspecific effects of vitamin C and
think that increased NO bioactivity is the most likely ex-
planation of our findings.
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